Teva Pharmaceutical Industries Ltd

Latest Results (07.08.2024):

Revenue Growth

Teva Pharmaceutical Industries Ltd. reported revenues of $15.8 billion for the full year 2023, reflecting an increase of 7% in local currency terms compared to 2022. This growth was driven by higher revenues from generic products in International Markets and Europe, as well as increased sales of innovative products like AUSTEDO and AJOVY.

Product Performance

AUSTEDO® achieved annual revenues exceeding $1.2 billion, marking a 28% increase from 2022. AJOVY® also saw significant growth, with global annual revenues reaching $435 million, up 16% from the previous year. Both products are expected to continue their strong performance into 2024.

Debt Reduction

Teva Pharmaceutical Industries Ltd. successfully reduced its net debt to $16.6 billion as of December 31, 2023. This ongoing debt reduction is part of the company's broader financial strategy to improve its balance sheet and allocate capital towards growth and innovation.

Financial Metrics

For Q4 2023, Teva reported revenues of $4.5 billion and a GAAP diluted earnings per share of $0.41. The non-GAAP diluted EPS for the quarter was $1.00. The company generated $1,184 million in cash flow from operating activities and $1,486 million in free cash flow during the quarter.

2024 Outlook

Teva Pharmaceutical Industries Ltd. has provided a positive outlook for 2024, with expected revenues ranging from $15.7 billion to $16.3 billion. The company anticipates a non-GAAP operating income of $4.0 to $4.5 billion, adjusted EBITDA of $4.5 to $5.0 billion, and a non-GAAP diluted EPS of $2.20 to $2.50. Free cash flow is projected to be between $1.7 billion and $2.0 billion.